• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Atricure Inc (NQ: ATRC )

    33.52 +0.02 (+0.04%)
    Streaming Delayed Price Updated: 2:04 PM EST, Nov 4, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Atricure Inc

    < Previous 1 2 3 4 5 Next >
    AtriCure to Announce Fourth Quarter and Full Year 2022 Financial Results and Participate in 2023 BTIG Medical Technology Conference
    From AtriCure, Inc.
    Via Business Wire
    AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2022, Provides Financial Outlook for 2023
    From AtriCure, Inc.
    Via Business Wire
    AtriCure to Participate in the 41st Annual J.P. Morgan Healthcare Conference
    From AtriCure, Inc.
    Via Business Wire
    5 Analysts Have This to Say About AtriCure
    Within the last quarter, AtriCure (NASDAQ:ATRC) has observed the following analyst ratings: 
    Via Benzinga
    Moderna To Rally Over 42%? Here Are 10 Other Price Target Changes For Monday
    Morgan Stanley cut VTEX (NYSE: VTEX) price target from $7 to $5.  Morgan Stanley analyst Cesar Medina downgraded the stock from Overweight to Equal-Weight. VTEX shares fell 4.9% to close at $3.52 on... 
    Via Benzinga
    AtriCure Wins 2022 NACD Diversity, Equity, & Inclusion Award
    From AtriCure, Inc.
    Via Business Wire
    AtriCure to Present at 34th Annual Piper Sandler Healthcare Conference
    From AtriCure, Inc.
    Via Business Wire
    AtriCure Reports Third Quarter 2022 Financial Results
    From AtriCure, Inc.
    Via Business Wire
    AtriCure to Participate in Upcoming Investor Conferences
    From AtriCure, Inc.
    Via Business Wire
    AtriCure to Announce Third Quarter 2022 Financial Results
    From AtriCure, Inc.
    Via Business Wire
    AtriCure Announces Investor Education Webcast with Hybrid AF Therapy Key Opinion Leaders
    From AtriCure, Inc.
    Via Business Wire
    AtriCure to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
    From AtriCure, Inc.
    Via Business Wire
    AtriCure: Q2 Earnings Insights
    AtriCure (NASDAQ:ATRC) reported its Q2 earnings results on Tuesday, August 2, 2022 at 04:01 PM. Here's what investors need to know about the announcement. Earnings AtriCure missed estimated earnings by... 
    Via Benzinga
    AtriCure Reports Second Quarter 2022 Financial Results
    From AtriCure, Inc.
    Via Business Wire
    AtriCure to Participate at Upcoming Investor Conferences
    From AtriCure, Inc.
    Via Business Wire
    5 Analysts Have This to Say About AtriCure
    Over the past 3 months, 5 analysts have published their opinion on AtriCure (NASDAQ:ATRC) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
    Via Benzinga
    AtriCure to Announce Second Quarter 2022 Financial Results
    From AtriCure, Inc.
    Via Business Wire
    Analyst Ratings for AtriCure
    Over the past 3 months, 4 analysts have published their opinion on AtriCure (NASDAQ:ATRC) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
    Via Benzinga
    AtriCure Announces the First Patient Treated in the HEAL-IST Clinical Trial
    From AtriCure, Inc.
    Via Business Wire
    AtriCure Announces the Appointment of Deborah Yount as Chief Human Resources Officer
    From AtriCure, Inc.
    Via Business Wire
    AtriCure's Q1 EPS Miss Estimates, Needham Lowers Price Target
    Needham lowered AtriCure Inc's (NASDAQ: ATRC) price target to $67 from $79 due to peer multiple compression, with the Buy rating unchanged. 
    Via Benzinga
    4 Analysts Have This to Say About AtriCure
    Over the past 3 months, 4 analysts have published their opinion on AtriCure (NASDAQ:ATRC) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
    Via Benzinga
    AtriCure: Q1 Earnings Insights
    AtriCure (NASDAQ:ATRC) reported its Q1 earnings results on Tuesday, May 3, 2022 at 04:01 PM. Here's what investors need to know about the announcement. Earnings AtriCure missed estimated earnings by... 
    Via Benzinga
    AtriCure Reports First Quarter 2022 Financial Results
    From AtriCure, Inc.
    Via Business Wire
    AtriCure Launches EnCompass® Clamp, a part of Isolator Synergy™ Ablation System
    From AtriCure, Inc.
    Via Business Wire
    AtriCure to Announce First Quarter 2022 Financial Results
    From AtriCure, Inc.
    Via Business Wire
    AtriCure Reports Deeper Losses In Q4 Despite 27% Jump In Sales, Issues FY22 Guidance
    AtriCure Inc (NASDAQ: ATRC) reported Q4 
    Via Benzinga
    Recap: AtriCure Q4 Earnings
    AtriCure (NASDAQ:ATRC) reported its Q4 earnings results on Tuesday, February 15, 2022 at 04:01 PM. Here's what investors need to know about the announcement. Earnings AtriCure missed estimated earnings... 
    Via Benzinga
    AtriCure Reports Fourth Quarter 2021 and Full Year 2021 Financial Results
    From AtriCure, Inc.
    Via Business Wire
    The Daily Biotech Pulse: Larimar Plunges On Extension Of Clinical Hold, ImmunityBio Gains On Positive Data, Adcom Test Awaits Avenue Therapeutics
    Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus ImmunityBio Says Cancer Combo Therapy Produces Positive Results In Late-Stage... 
    Via Benzinga
    < Previous 1 2 3 4 5 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.